{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:37:11Z","timestamp":1778153831495,"version":"3.51.4"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamaoncol.2018.6607","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T17:34:28Z","timestamp":1548956068000},"page":"623","source":"Crossref","is-referenced-by-count":27,"title":["Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy"],"prefix":"10.1001","volume":"5","author":[{"given":"St\u00e9phane","family":"Oudard","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[{"name":"Department of Oncology Radiotherapy, Clinique Pasteur, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Caty","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Galil\u00e9e, H\u00f4pital Priv\u00e9 la Louvi\u00e8re, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Miglianico","sequence":"additional","affiliation":[{"name":"Department of Oncology Radiotherapy, Centre Hospitalier Priv\u00e9 St Gr\u00e9goire, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Sevin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Fran\u00e7ois Baclesse, Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Claire","family":"Hardy-Bessard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,  H\u00f4pital Priv\u00e9 des C\u00f4tes d'Armor, Pl\u00e9rin, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remy","family":"Delva","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut de Canc\u00e9rologie de l'Ouest, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Rolland","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut de Canc\u00e9rologie de l'Ouest, St Herblain, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loic","family":"Mouret","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Priou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Hospitalier de Vend\u00e9e, La Roche sur Yon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beuzeboc","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Linassier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Hospitalier Bretonneau, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Oncology Radiotherapy, Centre Joliot Curie, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Voog","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinique Victor Hugo, Institut Inter-r\u00e9gional de Canc\u00e9rologie, Le Mans, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Muracciole","sequence":"additional","affiliation":[{"name":"Department of Oncology Radiotherapy, H\u00f4pital de la Timone, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Hospitalier Versailles Andr\u00e9 Mignot, Le Chesnay, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugeniu","family":"Banu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Ravaud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital St Andre, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Krakowski","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre Les Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-L\u00e9on","family":"Lagrange","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital Henri Mondor, Creteil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebl","family":"Deplanque","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondation Hopital St Joseph, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Zylberait","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Hospitalier de Compiegne, Compiegne, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bozec","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital Foch, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Houede","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Bergonie, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital St Louis, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Elaidi","sequence":"additional","affiliation":[{"name":"Association pour la Recherche sur les Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"17","key":"coi180114r1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy.","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"coi180114r2","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1097\/01.ju.0000091876.13656.2e","article-title":"The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.","volume":"170","author":"Ward","year":"2003","journal-title":"J Urol"},{"issue":"1","key":"coi180114r3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/bju.2012.109.issue-1","article-title":"The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.","volume":"109","author":"Antonarakis","year":"2012","journal-title":"BJU Int"},{"issue":"6, pt 1","key":"coi180114r4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1097\/01.ju.0000124381.93689.b4","article-title":"Validation of increasing prostate specific antigen as a predictor of PC death after treatment of localized PC with surgery or radiation.","volume":"171","author":"Albertsen","year":"2004","journal-title":"J Urol"},{"issue":"3","key":"coi180114r5","first-page":"130","article-title":"How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure.","volume":"17","author":"Jhaveri","year":"1999","journal-title":"Semin Urol Oncol"},{"issue":"28","key":"coi180114r6","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1200\/JCO.2005.01.2906","article-title":"Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.","volume":"23","author":"Zhou","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"coi180114r7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1200\/JCO.2006.08.0572","article-title":"Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.","volume":"25","author":"Freedland","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi180114r8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.2004.07.099","article-title":"Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.","volume":"22","author":"Scher","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi180114r9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.eururo.2015.11.023","article-title":"Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review.","volume":"69","author":"van den Bergh","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"coi180114r10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/01.ju.0000113794.34810.d0","article-title":"Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.","volume":"171","author":"Moul","year":"2004","journal-title":"J Urol"},{"issue":"4","key":"coi180114r11","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.ijrobp.2005.09.039","article-title":"Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10.","volume":"64","author":"Shipley","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"coi180114r12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi180114r13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaoncol.2016.3623","article-title":"Should chemotherapy be used in nonmetastatic PC?","volume":"3","author":"Graff","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi180114r14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaoncol.2016.3634","article-title":"Avoiding undertreatment of aggressive prostate cancer by early use of chemotherapy.","volume":"3","author":"Yu","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"coi180114r15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"coi180114r16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive PC.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10024","key":"coi180114r17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"coi180114r18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi180114r19","doi-asserted-by":"publisher","first-page":"e0157660","DOI":"10.1371\/journal.pone.0157660","article-title":"Efficacy and safety of combined androgen deprivation therapy (ADT) and docetaxel compared with ADT alone for metastatic hormone-naive PC: a systematic review and meta-analysis.","volume":"11","author":"Botrel","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"coi180114r20","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.2005.07.152","article-title":"Docetaxel followed by hormone therapy in men experiencing prostate-specific antigen after primary local treatments for PC.","volume":"23","author":"Hussain","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi180114r21","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.2005.11.111","article-title":"Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.","volume":"23","author":"Goodin","year":"2005","journal-title":"J Clin Oncol"},{"issue":"34","key":"coi180114r22","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1200\/JCO.2006.06.6589","article-title":"Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.","volume":"24","author":"Taplin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi180114r23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3816\/CGC.2006.n.009","article-title":"Weekly docetaxel\/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.","volume":"4","author":"Hainsworth","year":"2006","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"coi180114r24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"coi180114r25","doi-asserted-by":"publisher","first-page":"LBA5002","DOI":"10.1200\/jco.2015.33.15_suppl.lba5002","article-title":"A phase III protocol of androgen suppression (AS) and 3DCRT\/IMRT versus AS and 3DCRT\/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk PC (RTOG 0521)","volume":"33","author":"Sandler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi180114r26","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1002\/cncr.28270","article-title":"Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.","volume":"119","author":"Schweizer","year":"2013","journal-title":"Cancer"},{"issue":"20","key":"coi180114r27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"coi180114r28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response.","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi180114r29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/bju.2011.108.issue-3","article-title":"Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.","volume":"108","author":"Antonarakis","year":"2011","journal-title":"BJU Int"},{"issue":"4","key":"coi180114r30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive PC treated with androgen deprivation with or without docetaxel.","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi180114r31","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/jco.2015.33.15_suppl.5011","article-title":"Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +\/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi180114r32","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/annonc\/mdm083","article-title":"Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.","volume":"18","author":"Eymard","year":"2007","journal-title":"Ann Oncol"},{"issue":"15","key":"coi180114r33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"30","key":"coi180114r34","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","article-title":"Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.","volume":"28","author":"Franke","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi180114r35","first-page":"djv261","article-title":"The development of intermediate clinical endpoints in cancer of the prostate (ICECaP).","volume":"107","author":"Sweeney","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"coi180114r36","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized PC.","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi180114r37","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clon.2017.10.004","article-title":"Incorporating biomarker stratification into STAMPEDE: an adaptive multi-arm, multi-stage trial platform.","volume":"29","author":"Gilson","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"coi180114r38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/1758834017719215","article-title":"Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.","volume":"9","author":"Terada","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"coi180114r39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2018.04.083","article-title":"Androgen receptor\u2013targeted treatments for prostate cancer: 35 years\u2019 progress with antiandrogens.","volume":"200","author":"Crawford","year":"2018","journal-title":"J Urol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/5\/623\/17575115\/jamaoncology_oudard_2019_oi_180114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T16:59:30Z","timestamp":1557421170000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.6607"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.6607","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}